Hans Biomed Corporation appears in FDA premarket records as the applicant behind a series of 510(k) clearances for PDO-based surgical sutures reviewed by the General and Plastic Surgery panel. The supplied collection links one record, MINT MONO Sutures under K254238, decided Substantially Equivalent on September 18, 2026; that count reflects the retrieved filings as of the snapshot date and is not a measure of total portfolio, sales or safety performance. Earlier MINT filings in the numbered sources show how the product line has been described to FDA over time. [1][2][7]
The 2026 MINT MONO clearance
K254238 covers MINT MONO Sutures, received December 29, 2025 and decided September 18, 2026 as Substantially Equivalent. The submission was a Traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized Predetermined Change Control Plan. FDA records list the applicant address in Yuseong-Gu, Korea, with product code NEW, regulation 21 CFR 878.4840, Class 2, and advisory committee General, Plastic Surgery. A summary is noted as available. [1][2]
A device-level summary describes MINT MONO Sutures as PDO sutures indicated for soft tissue approximation where an absorbable suture is appropriate, and states they are not intended for lifting or filling aesthetic uses. The same summary describes them as smooth sutures and as part of the MINT Product Family of Sutures, with degradation and resorption over time. [7]
Earlier MINT family filings
K220549, decided March 7, 2023, covered the MINT Product Family including MINT, MINT Lift and MINT-I Sutures, with named models MINT Lift ML 1043, ML 1013, 1019 and MINT Lift Mini 1014. The clearance letter identifies the regulation as 21 CFR 878.4840, Class II, product code NEW, and states equivalence to the MINT Product Family cleared in K192423, also manufactured by Hans Biomed Corporation. Miracu (K172602), PDS Barbed Suture, PDO MAXX Threads (K190245), Demetech PDO Absorbable Suture (K082097), MINT (K130191) and Silhouette InstaLift (K163676) were listed as reference devices. [5]
K192423, cleared September 9, 2020, identified the MINT Product Family as an absorbable polydioxanone surgical suture under 21 CFR 878.4840, Class II, product code NEW, with Silhouette InstaLift as the predicate device. The decision letter was addressed to Hans Biomed Corporation through a regulatory consultant. [8]
Applicant identity and published company statements
Across the numbered filings, Hans Biomed Corporation is consistently the applicant or manufacturer of record for the MINT suture submissions; correspondence routes through consultants rather than establishing a corporate headquarters. Filing addresses are correspondence addresses and are not treated here as the company's headquarters. No parent, owner or brand relationship is verified in the public documents. [1][5][8]
Hans Biomed's own website describes the company as a bio-company developing high-tech medical materials for procedures and raw materials for medical supplies, and states it holds multiple first-in-class human tissue grafts and medical device products and operates a tissue engineering research lab. Those are company-published descriptions, not FDA findings. [6]
What the record does and does not show
The linked collection contains one 510(k) record with a Substantially Equivalent decision, and the record sample contains that same single entry; no recalls appear in the supplied recall sample. These are snapshot counts of retrieved filings, not evidence of total clearances, commercial availability, clinical performance or safety outcomes. [1]
The sources document suture composition, regulatory classification, review panel and stated indications for the MINT products. They do not establish pricing, customers, manufacturing capacity, certifications or post-market results, and none of those should be inferred from a clearance decision. [2][7]

